Overview

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Status:
Recruiting
Trial end date:
2021-11-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Cc-486
Lenalidomide